Entries by Nascent

Nascent Biotech Inc. Announces the Retirement of Its Convertible Debt

San Diego, CA September 17, 2015 – Nascent Biotech, Inc, (“Nascent” or “the Company”) (PINK.BB: NBIO) is pleased to announce that it has retired the $ 60,000 convertible debenture effective yesterday. The convertible debt could have potentially been converted into 6,000,000 shares of the Company’s common stock, thus diluting all the shareholders by nearly 30%. […]

Nascent Biotech Achieves Two Key Milestones in Development of its Novel Brain Cancer Treatment

San Diego, CA August 13, 2015 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO). Since March of 2014 Nascent has raised $2.1 million which has been used to advance the development of their core product, Pritumumab, to support the filing of an Investigational New Drug exemption (IND). Pritumumab is a fully human […]

Nascent Biotech, Inc. President Interviewed by The Stock Radio

San Diego, CA August 12, 2015 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), is pleased to release a recent interview with company President Sean Carrick, on The Stock Radio show.  It can be heard in full at: http://thestockradio.com/otcpink-nbio-nascent-biotech-inc-president-sean-carrick-2239.html In the interview, Mr. Carrick details that Nascent Biotech’s primary asset, Pritumumab, binds to a […]

Nascent Biotech, Inc. Announces 2 Additions to Scientific Advisory Board

San Diego, CA June 17, 2014 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announces announced that it has added two internationally renowned cancer experts to its scientific advisory board: Dr. Santosh Kesari is the director of the Neuro-Oncology Program, director of the Neurotoxicity Treatment Center, director of the Translational Neuro-Oncology Laboratories […]

Nascent Biotech, Inc. Begins Toxicology Trials

San Diego, CA, June 4th, 2015 – Nascent Biotech, Inc., (OTC.NBIO) Nascent Biotech, Inc announced that it has begun toxicology trials on its primary asset Pritumumab, a monoclonal antibody directed against a novel antigenic target on cancer cells. Pritumumab, a natural human IgG1 antibody, had been previously studied in brain cancer patients 20 years ago […]

Nascent Biotech Announces $225,000 NIH Grant Award in Conjunction with Mapp Biopharmaceutical

San Diego, CA, February 26th, 2015 – Nascent Biotech, Inc. (OTC: NBIO) and Mapp Biopharmaceutical announced today they have been awarded a $225,000 Small Business Innovative Research (SBIR) grant, titled “Novel Immunotherapy for Brain Cancer,” to fund initial development of tobacco plants as an adjunct expression system for Nascent Biotech’s lead candidate biopharmaceutical, Pritumumab, a […]

Nascent Biotech Inc. Raises $1.2 Million in Initial Funding

San Diego, CA, Nascent Biotech Inc (NBIO: OTC) announced today that it has recently closed a non-brokered private placement round for aggregate gross proceeds of $1.2Million. Management raised funds and the use of Proceeds will be for developing antibodies used to treat cancer; including manufacturing, preparation for human clinical trials, general working capital and administration. […]

2015 Human Antibodies & Hybridomas Conference

Nascent Biotech will be a key sponsor of the 2015 edition of the Human Antibodies & Hybridomas Conference, held October 28-30, 2015, at the University of Lausanne/CHUV, in Lausanne, Switzerland. Nascent Biotech CEO Mark Glassy will serve as the program chairman of the Scientific Advisory Committee. The conference scope will include: Infectious Diseases · Autoimmunity […]

Nascent team members author “Oligoclonal and Polyclonal Antibody Preparations” paper

Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta authored a new paper published in the Handbook of Therapeutic Antibodies, Second Edition, edited by Stefan Dübel and Janice M. Reichert (Wiley-VCH). Gupta, R. and Glassy, M. Oligoclonal and Polyclonal Antibody Preparations; in: Handbook of Therapeutic Antibodies; […]